APOA1 and triple-A syndrome: No significant differences were found for lipid, apoA-I and lipoprotein levels and almost all of the studied clinical parameters when they were compared among the three AAA progression groups, thereby indicating that these parameters were not related with AAA progression, at least in our sub-cohort of the VIVA trial.